



**FORM 7**  
**MONTHLY PROGRESS REPORT FOR THE MONTH ENDED AUGUST 31, 2020**

**Name of Listed Issuer:** MPX International Corporation (“MPXI” or the “Issuer”).

**Trading Symbol:** MPXI

**Number of Outstanding Listed securities:** 141,670,225

**Date:** September 8, 2020

*This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.*

*This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.*

**General Instructions**

- (a) *Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.*
- (b) *The term “Issuer” includes the Issuer and any of its subsidiaries.*
- (c) *Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.*

## Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

### MPXI introduced Canadian Retail Brand, Strain Rec™ to be used by Canveda

On August 5, 2020, the Issuer announced that its wholly-owned subsidiary, Canveda Inc. (“**Canveda**”), a licence holder under the *Cannabis Act* (Canada), launched its Canadian retail brand, *Strain Rec™*, with initial shipments made to the Province of Saskatchewan. The initial Strain Rec™ offering by Canveda consists purely of flower and was introduced to eight (8) Saskatchewan retailers during the last week of June by its Saskatchewan-approved distributor. The Issuer is also developing distribution channels for the Strain Rec™ brand with additional provincial cannabis marketing boards and will inform its shareholders of these developments in due course. For additional information on Strain Rec™ visit the website [www.strainrec.ca](http://www.strainrec.ca).

### Canveda entered into a Purchase Agreement with Zenabis Ltd. for the Supply of Cannabis

On August 12, 2020, the Issuer announced that Canveda entered into a purchase agreement for high quality cannabis flower from Zenabis Global Inc (“**Zenabis**”), a large-scale Canadian producer with an estimated 96,400 kg of licensed cannabis cultivation space.

The supply agreement between the parties secures Canveda 300 – 1,000 kg of cannabis flower per calendar quarter. The initial shipment of 100 kg will be sent to Israel as soon as an export permit from Health Canada is acquired. All the required import permits from Israel have been issued.

### Canveda entered into an Agreement for the Manufacturing and Distribution of Cannabis Products in Israel

On August 13, 2020, the Issuer announced that Canveda entered into a production and distribution agreement with Panaxia Pharmaceutical Industries Israel Ltd. (“**Panaxia**”), the largest manufacturer and distributor of medical cannabis products in Israel, for the packaging and distribution of cannabis which will be marketed and sold in Israel under Canveda's medical brand “Salus BioPharma”.

A first shipment of 100 kg of high-quality cannabis flower will be shipped from Canada to Israel as soon as an export permit from Health Canada is acquired. All the required import permits from Israel have been issued.

Panaxia uses high-quality cannabis flower to manufacture and distribute a variety of standardized, pharmagrade, smokeless, measured dosage cannabinoid-based products including sublingual tablets, slow release tablets, pastilles, rectal suppositories, vaginal suppositories, skincare ointments, topical patches and oral spray inhalers.

The Salus BioPharma products will be sold to patients with a variety of conditions such as PTSD, chronic pain, cancer, epilepsy, Parkinson's, Alzheimer's, anorexia and HIV/AIDS.

## MPXI Delayed Filing of Interim Financial Statements Pursuant to OSC Blanket Instrument 51-505

On August 27, 2020, the Issuer announced that, as a result of COVID-19, it was relying on the exemption provided in Ontario Instrument 51-505 - *Temporary Exemption from Certain Corporate Finance Requirements with Deadlines during the period from June 2 to August 31, 2020* of the Ontario Securities Commission, to delay the filing of MPXI's interim financial statements for the three and nine month period ended June 30, 2020 and related certifications and MPXI's management discussion and analysis for the three and nine month period ended June 30, 2020 (the "**Required Interim Filings**").

The officers and directors of the Issuer and certain other persons will remain subject to a trading black-out pursuant to which such persons are prohibited from trading in any securities of the Issuer until the end of the second full trading day following the day on which the Required Interim Filings are filed on SEDAR and a corresponding news release is issued by the Issuer.

The Issuer currently intends to make the Required Interim Filings by October 15, 2020.

**2. Provide a general overview and discussion of the activities of management.**

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at [www.sedar.com](http://www.sedar.com).

**3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None.

**4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

**5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at [www.sedar.com](http://www.sedar.com).

**6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

- 7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

- 8. Describe the acquisition of new customers or loss of customers.**

None.

- 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

Reference is made to Item (1) above, the Issuer's page on the CSE website and its profile at [www.sedar.com](http://www.sedar.com).

- 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None.

- 11. Report on any labour disputes and resolutions of those disputes if applicable.**

None.

- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None.

- 14. Provide details of any securities issued and options or warrants granted.**

None.

- 15. Provide details of any loans to or by Related Persons.**

None.

**16. Provide details of any changes in directors, officers or committee members.**

None.

**17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

The Issuer is a multinational diversified cannabis company focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis for the period ended March 31, 2020 (the "MD&A") under the headings "RISKS AND UNCERTAINTIES". The MD&A is available on the Issuer's SEDAR profile at [www.sedar.com](http://www.sedar.com) and the Issuer's page on the CSE website at [www.theese.com](http://www.theese.com).

In addition to the above, the Issuer may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact the Issuer by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Issuer may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Issuer is subject. Although the Issuer continues to operate in those jurisdictions in which its operations are permitted, there is no assurance that the Issuer's operations will continue to be deemed essential and/or will continue to be permitted to operate. Further, the Issuer may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition and the trading price of the Issuer's common shares.

## Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 8, 2020.

Jeremy S. Budd  
Name of Director or Senior Officer

signed "Jeremy S. Budd"  
Signature

Executive VP, General Counsel,  
Corporate Secretary and a director  
Official Capacity

|  |   |  |
|--|---|--|
| <b>Issuer Details</b><br>Name of Issuer<br>MPX International Corporation   | <b>For Month End</b><br>August 2020   | <b>Date of Report</b><br>YY/MM/DD<br>20/09/08  |
| <b>Issuer Address</b><br>5255 Yonge Street, Suite 701  |   |  |
| <b>City/Province/Postal Code</b><br>Toronto, Ontario, M2N 6P4  | <b>Issuer Fax No.</b><br>1-877-595-1828   | <b>Issuer Telephone No.</b><br>(416) 840-3725  |
| <b>Contact Name</b><br>W. Scott Boyes  | <b>Contact Position</b><br>Chairman,<br>President and CEO   | <b>Contact Telephone No.</b><br>(416) 840-3725 |
| <b>Contact Email Address</b><br><a href="mailto:info@mpxinternationalcorp.com">info@mpxinternationalcorp.com</a> | <b>Web Site Address</b><br><a href="http://www.mpxinternationalcorp.com">www.mpxinternationalcorp.com</a> |  |